CR9661A - Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso - Google Patents
Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su usoInfo
- Publication number
- CR9661A CR9661A CR9661A CR9661A CR9661A CR 9661 A CR9661 A CR 9661A CR 9661 A CR9661 A CR 9661A CR 9661 A CR9661 A CR 9661A CR 9661 A CR9661 A CR 9661A
- Authority
- CR
- Costa Rica
- Prior art keywords
- highly selective
- retoma
- norepinefrine
- inhibitor
- serotonin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan inhibidores de l aretoma de norepinefrina y serotonina duales altamente selectivos. Estos compuestos tiene un perfil de efcto colateral bajo y son utiles en composiciones y productos para uso en el tratamiento de una variedad de afecciones que incluyen depresion, fibromialgia, ansiedad, transtorno de panico, etc.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69966505P | 2005-07-15 | 2005-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9661A true CR9661A (es) | 2008-03-07 |
Family
ID=37453209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9661A CR9661A (es) | 2005-07-15 | 2007-01-15 | Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso |
Country Status (20)
Country | Link |
---|---|
US (1) | US20070015828A1 (es) |
EP (1) | EP1904434A2 (es) |
JP (1) | JP2009501229A (es) |
KR (1) | KR20080034921A (es) |
CN (1) | CN101223129A (es) |
AR (1) | AR057662A1 (es) |
AU (1) | AU2006270380A1 (es) |
BR (1) | BRPI0613031A2 (es) |
CA (1) | CA2615362A1 (es) |
CR (1) | CR9661A (es) |
EC (1) | ECSP088104A (es) |
GT (1) | GT200600308A (es) |
IL (1) | IL188614A0 (es) |
MX (1) | MX2008000680A (es) |
NO (1) | NO20080006L (es) |
PE (1) | PE20070247A1 (es) |
RU (1) | RU2007149183A (es) |
TW (1) | TW200740724A (es) |
WO (1) | WO2007011594A2 (es) |
ZA (1) | ZA200800408B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060134210A1 (en) * | 2004-12-22 | 2006-06-22 | Astrazeneca Ab | Solid dosage form comprising proton pump inhibitor and suspension made thereof |
CA2629609A1 (en) | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
WO2008013990A2 (en) | 2006-07-26 | 2008-01-31 | Teva Pharmaceutical Industries Ltd. | Processes for the synthesis of o-desmethylvenlafaxine |
US20090035370A1 (en) * | 2007-08-02 | 2009-02-05 | Drugtech Corporation | Dosage form and method of use |
KR101343027B1 (ko) | 2007-11-26 | 2013-12-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | O-데스메틸벤라팍신 푸마레이트의 결정형 |
US9339500B2 (en) * | 2008-03-04 | 2016-05-17 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
US20100016638A1 (en) * | 2008-07-21 | 2010-01-21 | Zdenko Hamersak | Method for preparation of o-desmethylvenlafaxine using polythiolates |
US8865937B2 (en) * | 2009-11-06 | 2014-10-21 | Mahendra G. Dedhiya | Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide |
WO2011121452A2 (en) | 2010-03-29 | 2011-10-06 | Pliva Hrvatska D.O.O. | Crystal forms of o-desmethylvenlafaxine fumarate |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
EP1360169B2 (en) * | 2001-02-12 | 2017-05-24 | Wyeth LLC | Succinate salt of o-desmethyl-venlafaxine |
CN1917860A (zh) * | 2004-02-06 | 2007-02-21 | 惠氏公司 | 多颗粒o-去甲基文拉法辛盐及其用途 |
RU2007132852A (ru) * | 2005-03-31 | 2009-05-10 | Вайет (Us) | Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение |
-
2006
- 2006-07-13 BR BRPI0613031-3A patent/BRPI0613031A2/pt not_active IP Right Cessation
- 2006-07-13 PE PE2006000834A patent/PE20070247A1/es not_active Application Discontinuation
- 2006-07-13 KR KR1020087003405A patent/KR20080034921A/ko not_active Application Discontinuation
- 2006-07-13 EP EP06786969A patent/EP1904434A2/en not_active Withdrawn
- 2006-07-13 AU AU2006270380A patent/AU2006270380A1/en not_active Abandoned
- 2006-07-13 MX MX2008000680A patent/MX2008000680A/es unknown
- 2006-07-13 JP JP2008521551A patent/JP2009501229A/ja not_active Withdrawn
- 2006-07-13 WO PCT/US2006/026991 patent/WO2007011594A2/en active Application Filing
- 2006-07-13 TW TW095125667A patent/TW200740724A/zh unknown
- 2006-07-13 CN CNA2006800258619A patent/CN101223129A/zh active Pending
- 2006-07-13 CA CA002615362A patent/CA2615362A1/en not_active Abandoned
- 2006-07-13 US US11/485,663 patent/US20070015828A1/en not_active Abandoned
- 2006-07-13 RU RU2007149183/04A patent/RU2007149183A/ru not_active Application Discontinuation
- 2006-07-13 AR ARP060103013A patent/AR057662A1/es unknown
- 2006-07-19 GT GT200600308A patent/GT200600308A/es unknown
-
2007
- 2007-01-15 CR CR9661A patent/CR9661A/es not_active Application Discontinuation
-
2008
- 2008-01-02 NO NO20080006A patent/NO20080006L/no not_active Application Discontinuation
- 2008-01-06 IL IL188614A patent/IL188614A0/en unknown
- 2008-01-14 EC EC2008008104A patent/ECSP088104A/es unknown
- 2008-01-14 ZA ZA200800408A patent/ZA200800408B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009501229A (ja) | 2009-01-15 |
ECSP088104A (es) | 2008-04-28 |
NO20080006L (no) | 2008-02-01 |
CN101223129A (zh) | 2008-07-16 |
KR20080034921A (ko) | 2008-04-22 |
WO2007011594A3 (en) | 2007-04-26 |
GT200600308A (es) | 2007-04-10 |
WO2007011594A2 (en) | 2007-01-25 |
TW200740724A (en) | 2007-11-01 |
ZA200800408B (en) | 2008-12-31 |
RU2007149183A (ru) | 2009-08-20 |
AU2006270380A1 (en) | 2007-01-25 |
CA2615362A1 (en) | 2007-01-25 |
PE20070247A1 (es) | 2007-04-11 |
IL188614A0 (en) | 2008-04-13 |
BRPI0613031A2 (pt) | 2012-01-03 |
MX2008000680A (es) | 2008-03-14 |
US20070015828A1 (en) | 2007-01-18 |
EP1904434A2 (en) | 2008-04-02 |
AR057662A1 (es) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9661A (es) | Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso | |
DOP2015000264A (es) | Derivados de azaadamantano y métodos de uso de los mismos | |
GT200900125A (es) | Nuevos derivados de 1,4-benzotiepina-1, 1-dioxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso. | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
PA8693101A1 (es) | Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso | |
CO6450665A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
UY30711A1 (es) | Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.- | |
CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
UY30712A1 (es) | Nuevos derivados de 1, 4-benzotiepina-1, 1-dioxido sustituidos con fluor, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
AR062875A1 (es) | Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos | |
CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
AR077629A1 (es) | Mimetico de smac | |
CR10782A (es) | Compuestos para inhibir la progresion mitotica | |
UY30710A1 (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales ciclohexilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso. | |
BRPI0510142A (pt) | compostos, composições e métodos para estabilizar a transtiretina e inibir a duplicação defeituosa da transtiretina | |
UY32464A (es) | Nuevos compuestos de indazol | |
CL2007002837A1 (es) | Uso de fenitoina para tratar mucositis oral. | |
BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
UY30511A1 (es) | Agonistas de ep2 | |
ECSP088743A (es) | Anticuerpos para egfl7 y métodos para su uso | |
CL2007000355A1 (es) | Combinacion que comprende un inhibidor de quinasas dependiente de ciclinas, un anticuerpo que inhibe un factor de crecimiento y un agente antimitotico; composicion farmaceutica que la comprende; y su uso para tratar un trastorno proliferativo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |